基石药业(02616.HK)抗PD-L1抗体完全缓解率达33.3%
基石药业-B(02616.HK)公布,公司於2019年美国血液学会年会上,以海报展示形式发表了S1001-201 研究的最新数据。CS1001-201是一项旨在评价CS1001单药治疗复发或难治性结外自然杀伤细胞的单臂、多中心II期临床研究。
基石药业首席医学官杨建新指,CS1001-201是全球范围内首个针对ENKTL的抗PD-L1 抗体临床研究。研究显示,相比在自体移植前获得部分缓解的患者,获得完全缓解的患者可以显着延长生存期、改善预後。最新研究数据显示,CS1001的完全缓解率为33.3%且缓解可持续,同时客观缓解率为43.3%,一年总生存率为72.4%,数据相比现有治疗选项是一个巨大的突破,并将可能为後续造血干细胞移植创造良好条件。 ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.